Amarin (AMRN) Issused Patent 8,324,195 for Vascepa
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Up)
Trade AMRN Now!
Amarin Corp Plc (NASDAQ: AMRN) announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent covering Amarin's Vascepa® (icosapent ethyl) capsules based on U.S. Patent Application Serial No. 13/349,150. On September 10, 2012, Amarin announced the issuance of a Notice of Allowance for claims under this application. The newly issued patent, U.S. Patent No.8,324,195, has a term that expires no earlier than in 2030.
"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has 10 U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"This patent issuance represents yet another step forward in Amarin's effort to protect the commercial potential of Vascepa," said Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's goal is to protect the commercial potential of Vascepa to beyond 2030 through patent protection, regulatory exclusivity and trade secrets and by taking advantage of manufacturing barriers to entry."
Amarin now has 10 U.S. patents either issued or allowed as well as over 30 additional patent applications currently in prosecution in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin (AMRN) Vascepa sNDA Set for Oct. 16, 2013, According to FDA
- Microsoft (MSFT) Announces Change to Xbox One Resell Rules (GME)
- Amarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
